Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing agreement with the Trump ...

Hetlioz (tasimelteon) has been approved in the US for a few years to treat sleep disorders affecting people who are blind or ...

In the same week that Servier announced its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has ...

The Cambridge, Massachusetts-based company – known as FogPharma until a rebrand in 2024 – needs cash for pivotal trials of ...

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

For over 60 years, the search for an effective pharmacologic treatment for refractory or unexplained chronic cough has been ...

Overall, it found that patients could lose up to a fifth of their body weight using the injectable GLP-1s, but put it back on ...

The ISPOR Glasgow panel conveyed a constructive, forward looking mood: JCA can work – and work better over time – if ...

Judges in the First US Circuit Court of Appeals in Boston have rejected an effort to overturn last month's injunction on the ...

The alliance with Paris, France-based Iktos could be worth more than €1 billion in upfront, research funding, and milestone ...

OpenAI has announced ChatGPT Health, which promises to bring users' medical records and health and wellness apps like Apple ...